Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Zura Bio LimitedNASDAQ: ZURA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 57.7% from a year ago
Other current liabilities stood at $1.13M at the end of Q1 FY2026, up 57.7% from a year earlier and down 65.9% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Other current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +57.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.32M USD
- Year-over-year change
- -82.3%
- 4-year CAGR
- +86.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.32M | -82.3% |
| FY2024 | 2024-12-31 | 18.78M | +1463.8% |
| FY2023 | 2023-12-31 | 1.2M | -56.7% |
| FY2022 | 2022-12-31 | 2.78M | +919.1% |
| FY2021 | 2022-03-31 | 272.29K | — |
Other Current Liabilities vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 other current liabilities of $1.13M is the 10th highest of the 11 companies compared; the peer median is $3.78M.
- Its year-over-year change of +57.7% is the 4th highest of 9, against a peer median of +17.8%.
- Other current liabilities amounts to 0.5% of total assets for ZURA, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.11B | +304928.8% | +7.5% | 1.4% | |
| Mar 2026 | $9.79M | — | -11.1% | 15.2% | |
| Mar 2026 | $5.49M | -13.6% | +19.8% | 2.2% | |
| Mar 2026 | $5.41M | +170.2% | +7.7% | 2.4% | |
| Mar 2026 | $3.92M | — | — | 1.2% | |
| Mar 2026 | $3.64M | -4.8% | -3.9% | 2.7% | |
| Mar 2026 | $2.64M | +5.9% | +83.3% | 1.5% | |
| Mar 2026 | $2.37M | +29.6% | +132.4% | 1.0% | |
| Mar 2026 | $1.52M | +204.8% | +280.2% | 1.5% | |
ZURAZura Bio Limited | Mar 2026 | $1.13M | +57.7% | +6.1% | 0.5% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $15K | -6.3% | -22.0% | 0.0% |
| Peer median (excluding ZURA) | $3.78M | +17.8% | +7.7% | 1.5% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.